Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

被引：0
|
作者：
Rothschild, S. I. [1 ]
Leger, P. [2 ]
Castellanos, E. L. [2 ]
Pillai, R. N. [3 ]
York, S. J. [2 ]
Horn, L. [2 ]
机构：
[1] Univ Spital Basel, Dept Internal Med, Med Oncol, Basel, Switzerland
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91PD-PR
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ocular adverse events in PD-1 and PD-L1 inhibitors
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen X.
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [32] Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
    Ming Yi
    Dechao Jiao
    Hanxiao Xu
    Qian Liu
    Weiheng Zhao
    Xinwei Han
    Kongming Wu
    Molecular Cancer, 17
  • [33] Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
    Yan, Ting
    Yu, Lun
    Shangguan, Dangang
    Li, Wei
    Liu, Ni
    Chen, Yun
    Fu, Yilan
    Tang, Jingyi
    Liao, Dehua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
  • [34] PD-1/PD-L1 inhibitors increase risk of hepatitis
    Reactions Weekly, 2020, 1809 (1) : 9 - 9
  • [35] Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
    Yi, Ming
    Jiao, Dechao
    Xu, Hanxiao
    Liu, Qian
    Zhao, Weiheng
    Han, Xinwei
    Wu, Kongming
    MOLECULAR CANCER, 2018, 17
  • [36] Trends in clinical development for PD-1/PD-L1 inhibitors
    Yu, Jia Xin
    Hodge, Jeffrey P.
    Oliva, Cristina
    Neftelinov, Svetoslav T.
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
  • [37] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
    Niemeijer, A.
    Smit, E.
    Van Dongen, G.
    Windhorst, A. D.
    Huisman, M.
    Hendrikse, N.
    Bahce, I.
    Lueng, D.
    Smith, R.
    Hayes, W.
    Wilson, L.
    Bonacorsi, S.
    Donnelly, D.
    Morin, P.
    Poot, A.
    Vugts, D.
    Thunnissen, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1817 - S1817
  • [39] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Shurong Wang
    Yuli Wang
    Hong Yan
    Medicinal Chemistry Research, 2023, 32 : 2089 - 2115
  • [40] Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
    Jelinek, Tomas
    Paiva, Bruno
    Hajek, Roman
    FRONTIERS IN IMMUNOLOGY, 2018, 9
12345